Last updated 16 days ago

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

1596 patients around the world
Available in Argentina, United States, Colombia, Brazil, Peru, Spain
Participants who have completed the study treatment period and have not been prematurely discontinued from IP in one of the predecessor studies, OBERON or TITANIA, will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo-controlled, Parallel Group, Phase 3 extension study to evaluate the efficacy and safety of Tozorakimab versus placebo in adult (40 years and older) participants with symptomatic COPD and with a history of exacerbations
AstraZeneca
1596Patients around the world

This study is for people with

Chronic obstructive pulmonary disease
Copd

Requirements for the patient

To 130 Years
All Gender

Medical requirements

LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy